Study of cell therapy for muscle injury meets primary safety, efficacy endpoints

Pluristem Therapeutics, a developer of placenta-based cell therapies based in Haifa, Israel, released on January 21 positive results from its phase I/II safety and efficacy trial of its PLX-PAD (placental expanded) cells for treatment of muscle injury.

Pluristem Therapeutics, a developer of placenta-based cell therapies based in Haifa, Israel, released on January 21 positive results from its phase I/II safety and efficacy trial of its PLX-PAD (placental expanded) cells for treatment of muscle injury.

Excerpt from:
Study of cell therapy for muscle injury meets primary safety, efficacy endpoints

Related posts:

  1. Feasibility, Safety, and Primary Efficacy of DermaStream: A Novel Continuously Streaming Device for Chronic Wounds
  2. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy
  3. A study to compare the efficacy of corticosteroid therapy with platelet-rich plasma therapy in recalcitrant plantar fasciitis: A preliminary report
  4. Arthroscopic triple fusion joint preparation using two lateral portals: a cadaveric study to evaluate efficacy and safety
  5. Cold Roller Muscle Therapy
  6. Safety and efficacy of tinea pedis and onychomycosis treatment in people with diabetes: a systematic review
  7. Efficacy and Safety of High-dose Vitamin C on Complex Regional Pain Syndrome in Extremity Trauma and Surgery—Systematic Review and Meta-Analysis -…
  8. Should We Revisit Accepted Endpoints In The Studies Of Modalities For Wound Healing?
  9. Efficacy and safety of the α4β2neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain
  10. Cell therapy for diabetic neuropathy